2020 American Society of Hematology Virtual Annual Meeting*

Download All
December 5-8, 2020; Online at https://www.hematology.org/meetings/annual-meeting
Review slidesets and expert analyses of key data from the 2020 Hematology Virtual Annual Meeting!

Multiple Myeloma

Capsule Summary Slidesets

Allogeneic CAR T-cell therapy with ALLO-715 (anti-BCMA) and ALLO-647 (anti-CD52) was well tolerated and showed promising activity in heavily pretreated patients with relapsed/refractory multiple myeloma.

Released: December 11, 2020

In this updated analysis, patients with a greater proportion of T-cells exhibiting a memory-like phenotype experienced greater CAR T-cell expansion and more durable responses.

Released: December 11, 2020

Preliminary data from phase I/II study on novel CAR T-cell therapy, P-BCMA-101, suggest safe and effective treatment for relapsed and refractory multiple myeloma.

Released: December 7, 2020

One-year outcomes from the phase II DREAMM-2 trial showed comparable outcomes with belantamab mafodotin in patients with R/R MM after either 3-6 or ≥ 7 prior lines of therapy.

Released: December 9, 2020

Preliminary analysis reported manageable safety profile and clinical activity with belantamab mafodotin plus bortezomib/dexamethasone in ongoing phase II trial of pretreated patients with MM.

Released: December 11, 2020

In patients with R/R MM receiving belantamab mafodotin, ocular AEs were common but manageable, with the majority of patients recovering while remaining on treatment.

Released: December 14, 2020

Initial results from the phase Ib/II study suggest ciltacabtagene autoleucel, an anti-BCMA CAR T-cell therapy, showed promising efficacy and a manageable safety profile in heavily pretreated patients with R/R MM.

Released: December 14, 2020

In this early study, the anti-BCMA ADC MEDI228 had manageable toxicity with responses seen at all dose levels in patients with heavily pretreated, relapsed/refractory multiple myeloma.

Released: December 14, 2020

Subcutaneous administration of teclistamab (JNJ-64007957) was well tolerated and associated with high response rates at the RP2D in an ongoing phase I trial of heavily pretreated patients with multiple myeloma.

Released: December 8, 2020

Initial results from this ongoing phase I study suggest that once-weekly administration of AMG 701 yields encouraging activity with the possibility for deep, durable responses, along with a manageable safety profile.

Released: December 7, 2020

After 4 years of follow-up, addition of daratumumab to lenalidomide/dexamethasone reduced the risk of progression or death by 46% and tripled the rate of MRD negativity.

Released: December 17, 2020

Bispecific antibody targeting GPCR5D, talquetamab, appears tolerable, safe, and efficacious in phase I data in patients with heavily pretreated relapsed/refractory MM.

Released: December 11, 2020

In this early study, anti-BCMA bispecific antibody REGN5458 showed promising efficacy and safety in heavily pretreated patients with R/R MM.

Released: December 15, 2020

Novel bispecific antibody targeting FcRH5, cevostamab, active and tolerable in heavily pretreated patients with R/R MM

Released: December 9, 2020

APOLLO met its primary endpoint of significantly improved PFS with daratumumab SC + Pd vs Pd only in patients with relapsed/refractory MM previously treated with lenalidomide and a PI.

Released: December 10, 2020

Data from the maintenance phase of GRIFFIN trial with D-VRd + DR maintenance led to significant improvement in sCR and depth of response vs VRd + R maintenance.

Released: December 9, 2020

The addition of ixazomib to Rd was reasonably well tolerated and conferred a clinically meaningful, but not statistically significant 13.5-month improvement in PFS compared with the control arm.

Released: December 9, 2020

The first clinical results of iberdomide in combination with either daratumumab/dex or bortezomib/dex is well tolerated with encouraging efficacy in heavily pretreated patients with myeloma.

Released: December 15, 2020

Combination of belantamab mafodotin with pomalidomide/dexamethasone resulted in high response rates in patients with relapsed/refractory multiple myeloma.

Released: December 8, 2020

All-oral regimen of selinexor/pomalidomide/low-dose dexamethasone appears to be highly active and have a manageable safety profile in patients with R/R MM after ≥ 2 previous therapies.

Released: December 10, 2020
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Amgen
AstraZeneca
Bristol-Myers Squibb
Epizyme Inc.
GlaxoSmithKline
Incyte Corporation
Janssen Biotech
Karyopharm Therapeutics Inc.
Novartis
PharmaEssentia Corp.
Seattle Genetics
Takeda Oncology

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue